ArticleInternational journal of chronic obstructive pulmonary disease2025
The Impact of Gut Microbiota on Chronic Obstructive Pulmonary Disease: A Dual-Sample Mendelian Randomization Study.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut microbiomes-host immune response and organ dysfunction across the gut-lung, gut-brain, and gut-liver axes.Frontiers in cellular and infection microbiology · 2026Review
- From the gut to the lungs: The role of gut microbiota in chronic obstructive pulmonary disease and related research progress.Microbial cell (Graz, Austria) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a major cause of global mortality and disability. Previous research suggests a relationship between gut microbiota and COPD, yet the causal link remains unclear. Hence, we conducted a dual-sample Mendelian randomization study to elucidate the impact of gut microbiota on COPD. Methods: We utilized single-nucleotide polymorphisms (SNPs) as instrumental variables, and the Inverse Variance Weighted (IVW) method for primary analysis. We explored the causal linkage between gut microbiota species (Coprococcus2, Holdemanella, Allisonella, Anaerostipes, Lachnospiraceae UCG008, Lachnospiraceae UCG010, Prevotella9, Marvinbryantia, Ruminococcaceae UCG013) and COPD through the analysis of genome-wide association study (GWAS) data sourced from a Finnish database. Summary data for COPD (6,915 cases and 186,723 controls), Early onset COPD (3,508 cases and 212,197 controls), admission rate of COPD (9,113 cases and 212,292 controls), related infection of COPD (59,925 cases and 159,867 controls), respiratory dysfunction of COPD (1,031 cases and 186,723 controls), were from FinnGen consortium R7 GWAS. Result: Our analysis revealed statistically significant correlations between several genera and COPD. Coprococcus2 exhibits a consistent protective role throughout the progression of COPD, evident in both typical COPD [OR=0.750, 95% CI (0.601-0.937)], early-onset cases [OR=0.686, 95% CI (0.511-0.920)], COPD-related hospitalizations [OR=0.724, 95% CI (0.575-0.910)] and infections [OR=0.301, 95% CI (0.094-0.961)]. Holdemanella manifests as a consistent risk factor in the COPD incidence [OR=1.211, 95% CI (1.063-1.380)], early-onset COPD [OR=1.214, 95% CI (1.019-1.446)], COPD hospitalization [OR=1.225, 95% CI (1.072-1.401)] and respiratory impairment (OR:1.645, 95% CI: 1.198-2.258). Allisonella demonstrates protective attributes in COPD occurrence [OR=0.884, 95% CI (0.794-0.984)]. Genera such as Anaerostipes, Lachnospiraceae UCG008, Lachnospiraceae UCG010, and Prevotella9 show protective effects specifically in early-onset COPD. Marvinbryantia and Ruminococcaceae UCG013 are consistently identified as risk factors in onset of typical COPD. Conclusion: Mendelian randomization studies confirm a causal link between gut microbiota and various COPD types and complications, offering new insights into the disease's pathogenesis, prevention, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.